CytoMed Therapeutics Limited (GDTC)
NASDAQ:GDTC
Want to see GDTC full AI Analyst Report?
Top Page
CytoMed Therapeutics Limited
(NASDAQ:GDTC)
Select Model
Select Model
Rating:51Neutral
Price Target:
$1.50
▲(7.91% Upside)
Action:Reiterated
Date:05/21/26
The score is held back primarily by weak financial performance (persistent losses and accelerating cash burn), only partially offset by an improved balance sheet. Technicals are relatively supportive in the near term, but valuation remains constrained by lack of profitability and no dividend.
Positive Factors
Clinical pipeline progress
Advancing Phase I trials and external research ties indicate tangible R&D progression and a de-risking path for future productization. Over 2–6 months, dose escalation, multi-site enrollment and high-quality collaborations strengthen the company's ability to generate clinical data that underpins long-term commercialization potential.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow and a steep cash decline materially increase financing dependency. Over months, this raises the likelihood of dilutive capital raises or restrictive financing terms, pressuring strategic optionality and potentially slowing clinical or commercial initiatives without new funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical pipeline progress
Advancing Phase I trials and external research ties indicate tangible R&D progression and a de-risking path for future productization. Over 2–6 months, dose escalation, multi-site enrollment and high-quality collaborations strengthen the company's ability to generate clinical data that underpins long-term commercialization potential.
Read all positive factors
CytoMed Therapeutics Limited (GDTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.44M
Dividend YieldN/A
Average Volume (3M)166.79K
Price to Earnings (P/E)―
Beta (1Y)0.10
Revenue Growth373.88%
EPS Growth-59.79%
CountryUS
Employees43
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,832,835
10 Day Avg. Volume104,297
30 Day Avg. Volume166,789
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)2.38
Price to Sales (P/S)48.89
P/FCF Ratio-3.55
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue31.46
Enterprise Value/Gross Profit-32.29
Enterprise Value/Ebitda-3.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CytoMed Therapeutics Limited Business Overview & Revenue Model
Company Description
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma de...
How the Company Makes Money
null...
CytoMed Therapeutics Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 319.20K | 52.01K | 290.56K | 0.00 | 84.18K |
| Gross Profit | ― | 52.38K | 381.92K | -81.03K | 81.59K |
| EBITDA | -4.30M | -1.79M | -2.94M | -1.10M | -1.05M |
| Net Income | -3.92M | -1.88M | -3.13M | -2.27M | -1.53M |
Balance Sheet | |||||
| Total Assets | 7.98M | 7.37M | 9.37M | 3.90M | 4.51M |
| Cash, Cash Equivalents and Short-Term Investments | 2.10M | 3.64M | 6.82M | 1.18M | 1.87M |
| Total Debt | 482.56K | 339.20K | 339.50K | 3.15M | 2.42M |
| Total Liabilities | 1.13M | 749.76K | 852.28K | 3.46M | 2.59M |
| Stockholders Equity | 6.54M | 6.57M | 8.52M | 438.24K | 1.92M |
Cash Flow | |||||
| Free Cash Flow | -4.40M | -3.01M | -2.72M | -1.40M | -1.70M |
| Operating Cash Flow | -3.70M | -1.98M | -2.68M | -1.04M | -1.27M |
| Investing Cash Flow | 929.28K | 494.59K | -2.11M | -353.37K | -610.72K |
| Financing Cash Flow | 208.65K | -33.36K | 8.16M | 793.25K | 3.09M |
CytoMed Therapeutics Limited Technical Analysis
Positive
1.39
Price Trends
1.01
Positive
1.04
Positive
1.49
Negative
Market Momentum
0.06
Negative
56.27
Neutral
76.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDTC, the sentiment is Positive. The current price of 1.39 is above the 20-day moving average (MA) of 0.98, above the 50-day MA of 1.01, and below the 200-day MA of 1.49, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 56.27 is Neutral, neither overbought nor oversold. The STOCH value of 76.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GDTC.
CytoMed Therapeutics Limited Risk Analysis
CytoMed Therapeutics Limited disclosed 106 risk factors in its most recent earnings report. CytoMed Therapeutics Limited reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CytoMed Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $14.82M | -0.38 | -229.48% | ― | ― | 83.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $14.44M | -3.98 | -42.29% | ― | 373.88% | -59.79% | |
48 Neutral | $5.88M | >-0.01 | -68.21% | ― | ― | ― | |
42 Neutral | $16.55M | -0.83 | -135.04% | ― | ― | 42.29% |
* Healthcare Sector Average
GDTC
CytoMed Therapeutics Limited
1.13
-1.25
-52.52%
AKTX
Akari Therapeutics
18.27
-35.13
-65.79%
MTVA
MetaVia
3.85
-4.64
-54.65%
PASG
Passage Bio
5.23
-1.94
-27.03%
KAPA
Kairos Pharma, Ltd.
0.55
-0.02
-4.39%
CytoMed Therapeutics Limited Corporate Events
CytoMed Chairman Moves to Boost Personal Stake Through Private Share Purchases
May 15, 2026
On May 13, 2026, CytoMed Therapeutics Limited’s chairman and director, Choo Chee Kong, entered into a binding private share purchase agreement with an independent arm’s-length shareholder to acquire 112,000 ordinary shares for cash in ...
CytoMed Renames Subsidiary to Drive Asian and International Expansion
May 11, 2026
On May 6, 2026, CytoMed Therapeutics said its wholly owned subsidiary, established in 2020 as Advance Cancer Centre Pte. Ltd., had been renamed CytoMed International Pte. Ltd. The rebranding underscores a strategic push to grow the group’s g...
CytoMed Therapeutics Sets May 22, 2026 AGM With Expanded Share-Issuance Mandate on the Table
Apr 14, 2026
CytoMed Therapeutics Limited has called its Annual General Meeting of shareholders for May 22, 2026, in Singapore, with an option for overseas investors to follow proceedings via a live webcast. The agenda includes adopting the 2025 financial stat...
CytoMed Therapeutics Widens 2025 Loss as It Accelerates Cell Therapy Trials and Southeast Asia Expansion
Mar 31, 2026
On March 31, 2026, CytoMed Therapeutics reported audited results for the year ended December 31, 2025, showing revenue and other operating income of US$780,857 and a wider net loss of US$3.11 million, driven partly by higher research, employee and...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.